Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published-Ahead-of-Print August 26, 2010, DOI:10.2164/jandrol.110.011163

This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
32/2/159    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chung, S.-D.
Right arrow Articles by lin, H.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, S.-D.
Right arrow Articles by lin, H.-C.

Increased Risk of Benign Prostatic Enlargement among Patients with Liver Cirrhosis: A Nationwide Population-Based Study

Shiu-Dong Chung and Herng-Ching lin *

* To whom correspondence should be addressed. E-mail: henry11111{at}tmu.edu.tw.

There have been several post mortem studies focusing on the association between liver cirrhosis and benign prostate hyperplasia, however, the results are controversial. The aim of this study is to estimate the risk of benign prostatic enlargement during a five-year follow-up period following a liver cirrhosis diagnosis, using nationwide population-based data and a retrospective cohort design. We used the "Longitudinal Health Insurance Database," derived from the Taiwan National Health Insurance program. The study cohort comprised 661 patients who had received treatment for liver cirrhosis between 1997 and 2001; 3,305 randomly selected subjects comprised the comparison cohort. Stratified Cox proportional hazard regressions were performed as a means of comparing the five-year benign prostatic enlargement survival rate for the two cohorts. Of the sampled patients, 808 patients (20.4%) developed benign prostatic enlargement during the follow-up period, that is, 163 individuals from the study cohort (24.7% of the patients with liver cirrhosis) and 645 individuals from the comparison cohort (19.5% of comparison cohort patients). The log rank test indicated that patients with liver cirrhosis had significantly lower five-year benign prostatic enlargement-free survival rates than the controls (P<0.001). The adjusted hazard ratios for benign prostatic enlargement following diagnosis with liver cirrhosis were 1.41 during the five-year follow-up period. We conclude that the risk for benign prostatic enlargement increased after a diagnosis of liver cirrhosis. Further studies are needed to identify the underlying pathophysiology.


Key words: Prostate • liver cirrhosis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2010 by The American Society of Andrology.